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Background: The association between depression, anxiety, and polycystic ovary syndrome 
(PCOS) is still unclear. Therefore, a systematic review and meta-analysis was conducted to 
assess the rates of comorbid psychiatric disorders among women with PCOS compared to 
women without it.
Methods: PubMed/MEDLINE, Embase, PsycINFO, and Web of Science databases were 
searched from inception to November 27, 2015. Studies were eligible for inclusion if they were 
original reports in which the rates of mood (bipolar disorder, dysthymia, or major depressive 
disorder), obsessive–compulsive spectrum disorders, trauma- and stressor-related disorders, 
anxiety disorders or psychotic disorders, somatic symptom and related disorders, or eating 
disorders had been investigated among women with an established diagnosis of PCOS and 
compared with women without PCOS. Psychiatric diagnosis should have been established by 
means of a structured diagnostic interview or through a validated screening tool. Data were 
extracted and pooled using random effects models.
Results: Six studies were included in the meta-analysis; of these, five reported the rates of 
anxiety and six provided data on the rates of depression. The rate of subjects with anxiety 
symptoms was higher in patients with PCOS compared to women without PCOS (odds ratio 
(OR) =2.76; 95% confidence interval (CI) 1.26 to 6.02; Log OR =1.013; P=0.011). The rate 
of subjects with depressive symptoms was higher in patients with PCOS compared to women 
without PCOS (OR =3.51; 95% CI 1.97 to 6.24; Log OR =1.255; P,0.001).
Conclusion: Anxiety and depression symptoms are more prevalent in patients with PCOS.
Keywords: polycystic ovary syndrome, depression, anxiety, epidemiological survey, meta-
analysis, systematic review
Introduction
Polycystic ovary syndrome (PCOS) is a complex genetic disease that affects approxi-
mately 7% of women of reproductive age worldwide.1 PCOS is a heterogeneous dis-
order, where the main clinical features include menstrual irregularities, subfertility, 
hyperandrogenism, and hirsutism.2
Numerous studies have evaluated the relation between PCOS and psychiatric 
disorders; however, most have evaluated psychiatric symptoms based on self-report 
measures.1,3 There remains, therefore, an unclear relationship between PCOS and 
psychiatric disorders. Cross-sectional epidemiological studies have reported that 
individuals with PCOS are more likely to have anxiety or depressive disorders when 
compared to those in the general population.4 Two studies have shown depression, 
bipolar disorder, anxiety disorders, and binge eating disorder are more frequent among 
women with PCOS compared with controls.5,6
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PCOS is accompanied by an array of symptoms such 
as obesity, acne, scalp hair thinning, menstrual irregular-
ity, and subfertility. These symptoms can also contribute 
to psychological impairment.7 Despite the use of antide-
pressants in the treatment of depressive symptoms, there 
has been only one report to date on the use of serotonin 
reuptake inhibitors with a successful outcome in a patient 
with PCOS.8
In light of the above mentioned, the purpose of the 
present study is to perform a systematic review and meta-
analysis of the rates of mood (bipolar disorder, dysthymia, or 
major depressive disorder), obsessive–compulsive spectrum 
disorders, trauma- and stressor-related disorders, anxiety dis-
orders, psychotic disorders, somatic symptom and related 
disorders, binge eating disorders and eating disorders among 
women with an established diagnosis of PCOS compared to 
those without PCOS.
Materials and methods
A systematic review and meta-analysis was performed in 
accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) and the Cochrane 
group guideline recommendations.9,10 The process includes 
literature review, eligibility criteria of the retrieved refer-
ences, assessment of the methodological quality of included 
studies, extraction of outcomes and relevant variables, and 
meta-analysis of the data.
Search strategy
We searched the PubMed/MEDLINE, Embase, PsycINFO, 
and Web of Science databases from inception to November 27, 
2015. This search strategy was augmented by hand-searching 
through reference lists of included articles and by tracking the 
citations of eligible references in Google Scholar.
eligibility criteria
We included original reports in which the rates of mood 
(bipolar disorder, dysthymia, or major depressive disorder), 
obsessive–compulsive spectrum disorders, trauma- and 
stressor-related disorders, anxiety disorders, psychotic dis-
orders, somatic symptom and related disorders, and eating 
disorders have been investigated among women with an 
established diagnosis of PCOS and compared to women 
without PCOS. Psychiatric diagnosis should have been 
established by means of a structured diagnostic interview 
according to either Diagnostic and Statistical Manual of 
Mental Disorders (DSM) or International Classification 
of Diseases (ICD) criteria. Studies in which a diagnosis 
of psychiatric disorder had been established through a 
validated screening tool above a preestablished cutoff 
were also considered for inclusion. A diagnosis of PCOS 
could be established by means of the Rotterdam, National 
Institutes of Health (NIH), or PCOS Society criteria.11 We 
included original peer-reviewed studies published in English, 
Portuguese, French, Spanish, or German. Either population-
based or studies performed in clinical samples were eligible 
for inclusion. Meeting abstracts were excluded. We also 
excluded studies performed in pediatric populations.
Outcomes
The primary outcome was the odds ratios (ORs) of psychiat-
ric disorders among women with PCOS compared to women 
without PCOS.
Search strategy (November 27, 2015)
PubMed/MeDLiNe
•	 Search 1: ((((((((“Depression”[Mesh] OR “Depressive 
Disorder”[Mesh] OR “Depression, Postpartum”[Mesh] 
OR “Depressive Disorder, Major”[Mesh] OR “Bipolar 
Disorder”[Mesh]) OR “Anxiety Disorders”[Mesh]) 
OR “Phobic Disorders”[Mesh]) OR “Stress Disorders, 
Post-Traumatic”[Mesh]) OR “Obsessive-Compulsive 
Disorder”[Mesh]) OR “Psychotic Disorders”[Mesh]) 
OR (“Schizophrenia”[Mesh] OR “Schizophrenia 
and Disorders with Psychotic Features”[Mesh])) 
OR “Somatoform Disorders”[Mesh]) OR (“Eating 
Disorders”[Mesh] OR “Binge Eating Disorder”[Mesh]) 
Field: Title/Abstract.
•	 Search 2: “Polycystic Ovary Syndrome”[Mesh] Field: 
Title/Abstract.
•	 Search 3: #1 AND #2.
•	 Retrieved references: 171.
OviD databases (PsyciNFO and embase Classic plus 
embase)
•	 Search 1: “polycystic ovary syndrome”.ti,ab,kw
•	 Search 2: (“depression” or “depressive disorder” or 
“major depressive disorder” or “bipolar disorder” or 
“mania” or “postpartum depression” or “somatoform 
disorder” or “binge eating disorder” or “eating disorder” 
or “anxiety disorder” or “post-traumatic stress disorder” 
or “obsessive compulsive disorder” or “psychosis” or 
“psychotic disorder” or “schizophrenia” or “bulimia” or 
“anorexia nervosa”).
•	 Search 3: #1 and #2.
•	 Retrieved References: 360.
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Selection of eligible studies
•	 This systematic review complied with PRISMA 
guidelines;
•	 the primary (ie, title/abstract) screening was indepen-
dently performed by two researchers (SLB and JVAA), 
supervised by ICP, who made the final decision in cases 
of disagreement;
•	 the PDFs (ie, full-texts) of potentially eligible articles 
were retrieved;
•	 the secondary screening was independently performed 
by two researchers (SLB and JVAA), supervised by ICP, 
who made the final decision in cases of disagreement;
•	 disagreements were resolved through consensus.
Quality assessment
We used the Newcastle–Ottawa Quality Assessment Scale 
(NOQAS) to assess the quality of included studies.12 Overall 
quality score was defined as the percentage of criteria that 
were met by each included study. We excluded NOQAS 
items 4 and 7 because these were meaningless for the context 
of the current study. The agreement of independent raters 
(SLB and JVAA) was excellent (Cohen’s kappa =0.91; 
standard error (SE) =0.05).
Data extraction
We built Excel spreadsheets to extract data from included 
articles. We used the version X7 of EndNote to remove 
duplicate data. The characteristics extracted from each study 
were: name of the first author; publication year; country; 
number, sex, and age of the patients and controls; type of 
diagnostic criteria used to assess PCOS (Rotterdam, NIH, 
or PCOS Society) and the psychiatric disorders (DSM or 
ICD); whether patients were medication free; latitude of the 
city where the study was performed; mean age of the total 
sample size; type of study (population-based or clinical 
study); whether the diagnoses of psychiatric disorders were 
assessed through structured interviews; NOQAS items.
Data analysis
We used the metaphor package for R (version number 3.2.3) 
to do the meta-analysis with binary data and meta-regression 
analysis.13 We undertook meta-analyses whenever values 
of the rate of a specific psychiatric disorder in patients with 
PCOS compared to healthy controls were available in two 
or more studies.13 A random-effects model with restricted 
maximum-likelihood estimator was used to synthesize the 
effect size across studies. This model can incorporate both 
within-study variability and between-study variability.13 
The OR and Log OR were used to assess the effect size.8 The 
significance level for this meta-analysis model was 0.05.13 
Egger’s linear regression test was used to assess publication 
bias. This is a test for asymmetry of the funnel plot, and it 
was done whenever three or more studies were included.14 For 
this specific test a P-value of less than 0.1 shows significant 
asymmetry and therefore publication bias.14 If Egger’s linear 
regression test revealed a potential publication bias, we used 
Duval and Tweedie’s trim and fill method to test the data. 
We also used the so-called leave-one-out function for doing 
sensitivity analysis.13 This method consists of the removal of 
one study at a time from the dataset to run the meta-analysis 
without it. This analysis tests if the effect size of the meta-
analysis is driven by one study. We used the Q statistic 
to test the existence of heterogeneity and I2 to assess the 
proportion of total variability due to heterogeneity.15 An 
I2 value of ~25% could be regarded as low, ~50% as medium, 
and ~75% as high.9 We used τ2 to estimate the total amount 
of heterogeneity.15
We explored sources of heterogeneity in studies using 
univariate meta-regression analysis.16,17 We selected the 
latitude of the city where the study was performed, type of 
diagnostic criteria used to define PCOS, mean age of the total 
sample size of the included studies, type of study, total sample 
size of the PCOS group of the included studies, whether the 
diagnoses of psychiatric disorders were assessed through 
structured interviews, and quality of the included studies as 
assessed by the NOQAS as moderator. A pseudo-R2 statistic 
is given for each analysis, showing the percentage of total 
heterogeneity in the true effects that is accounted for by the 
model with all covariates included.
Results
Figure 1 shows the study selection process. Quality and char-
acteristics of included studies are described in Table 1.
Anxiety symptoms
A total of five studies were included in this meta-analysis.18–22 
The rate of subjects with anxiety symptoms was higher in 
patients with PCOS compared to healthy controls (OR =2.76; 
95% confidence interval (CI) 1.26 to 6.02; Log OR =1.013; 
P=0.011). Figure 2 shows the forest plot and the OR of the 
pooled analysis (Log scale was used in the x axis) while 
Figure 3 shows the funnel plot (Log OR was used for the 
funnel plot). Egger’s linear regression test revealed potential 
publication bias (z=1.869, P=0.061). We, therefore, performed 
Duval and Tweedie’s trim and fill method, and the result for 
the rate of anxiety symptoms in patients with PCOS was still 
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higher compared to healthy controls (OR =2.40; 95% CI 1.16 
to 4.97; Log OR =0.874; P=0.018 – one study was estimated 
on the left side). The significance of the effect size remained 
robust when leave-one-out models were used for such meta-
analysis (see Table 2 – results were presented with Log OR). 
No significant heterogeneity was found (Q statistic =8.345, 
df=4, P=0.079; I2=51.73%; τ2=0.389). In our investigation 
of covariates using univariate meta-regression analyses, we 
found that latitude of the city where the study was performed 
(estimate =0.010; 95% CI -0.013 to 0.034; P=0.375), type 
of diagnostic criteria used to define PCOS (estimate =0.393; 
95% CI -1.452 to 2.240; P=0.675), mean age of the total 
sample size of the included studies (estimate =-0.123; 95% 
CI -0.264 to 0.017; P=0.085), type of study (estimate =0.393; 
95% CI -1.452 to 2.240; P=0.675), total sample size of the 
PCOS group of the included studies (estimate =0.012; 95% 
CI -0.032 to 0.056; P=0.597) and whether the diagnoses 
of psychiatric disorders were assessed through structured 
interviews (estimate =-1.307; 95% CI -3.848 to 1.233; 
P=0.313) did not moderate the effect size. It is worth men-
tioning that quality of the included studies as assessed by the 
Newcastle–Ottawa Scale also did not moderate the effect size 
(estimate =-0.711; 95% CI -1.317 to -0.104; P=0.021).
Depressive symptoms
A total of six studies were included in this meta- 
analysis.18–20,22,23 The rate of subjects with depressive 
symptoms was higher in patients with PCOS compared 
????????????????????????????????????????????????????? ??????????????????????????????????????????????????????
???????????????????????????????????
???????????????????????????????????????????????????????????????
??????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????
????
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?
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Figure 1 PRISMA flowchart of systematic review.
Abbreviations: PCOS, polycystic ovary syndrome; NiH, National institutes of Health.
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to healthy controls (OR =3.51; 95% CI 1.97 to 6.24; Log 
OR =1.255; P,0.001). Figure 4 shows the forest plot and 
the OR of the pooled analysis (Log scale was used in the 
x axis) while Figure 5 shows the funnel plot (Log OR was 
used for the funnel plot). Egger’s linear regression test 
revealed no potential publication bias (z=0.499, P=0.618). 
The significance of the effect size remained robust when 
leave-one-out models were used for such meta-analysis (see 
Table 3 – results were presented with Log OR). We found no 
significant between-study heterogeneity (Q statistic =6.055, 
df=5, P=0.301; I2=22.17%; τ2=0.338). In our investigation 
of covariates using univariate meta-regression analyses, we 
found the city’s latitude where the study was performed 
(estimate =0.005; 95% CI -0.012 to 0.022; P=0.551), type 
of diagnostic criteria used to define PCOS (estimate =-0.606; 
95% CI -1.926 to 0.713; P=0.367), mean age of the total 
sample size of the included studies (estimate =-0.069; 95% 
CI -0.201 to 0.061; P=0.298), type of study (estimate =-0.606; 
95% CI -1.926 to 0.713; P=0.367), total sample size of the 
PCOS group of the included studies (estimate =0.011; 95% 
CI -0.009 to 0.032; P=0.284), and whether the diagnoses 
of psychiatric disorders were assessed through structured 
interviews (estimate =-0.531; 95% CI -3.485 to 2.422; 
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Figure 2 Forest plot of the studies assessing anxiety symptoms.
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Figure 3 Funnel plot of the studies that assessed anxiety symptoms.
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P=0.724) did not moderate the effect size. It is worth 
mentioning that quality of the included studies as assessed by 
the Newcastle–Ottawa Scale also did not moderate the effect 
size (estimate =-0.131; 95% CI -0.929 to 0.667; P=0.747). 
We did not analyze structured psychiatric diagnosis as a 
moderator since no study used it.
Discussion
This systematic review found six studies that study the asso-
ciation of PCOS with depression or anxiety in young women 
(22.4 to 32 years old in the PCOS group and 24.9 to 36.4 years 
old in the control group) in clinical settings, performed in 
four countries (Turkey, Australia, Brazil, United States). 
Methodologically, all studies selected were performed in 
clinical settings, with a good overall assessment of quality, 
although they showed some different characteristics, such as 
sample size (between 46 and 206 individuals), differences 
in the criteria used to diagnose PCOS as well as a difference 
in the instruments used to assess anxiety and/or depression. 
Particularly, the lack of a unified concept of PCOS and 
differences in the assessment of psychiatric diagnosis across 
studies hindered comparisons. However, we were not able to 
identify potential sources of heterogeneity (latitude, type of 
diagnostic criteria used to define PCOS, mean age, type of 
study, total sample size of the PCOS group, assessment of psy-
chiatric disorders, and methodological quality of the study). 
These results should be considered exploratory in nature as 
few studies may undermine the statistical power of meta-
regression techniques.
Overall, in the present meta-analysis, we found that rates 
of anxiety and depressive symptoms were higher in patients 
with PCOS compared to healthy controls in line with dis-
tinct clinical studies suggesting the increased prevalence of 
anxiety and depression in women with PCOS.
Clinical and research implications
Results from this systematic review indicate that special-
ized literature shows that a limited number of studies have 
assessed the prevalence of psychiatric conditions in women 
with PCOS compared to healthy controls. Only six studies 
were selected. The main finding was that women with PCOS 
have a higher prevalence rate of anxiety and depression.
Potential mechanisms for these associations may include 
social, psychological, and neurobiological aspects. Women 
with PCOS may report clinically significant symptoms of 
anxiety or depression at least in part as a result of significant 
body changes imposed by their illness (eg, hirsutism, irregu-
lar menses, obesity, acne, hair thinning).2,7 Previous research 
indicates that alterations in body image may contribute to 
psychological distress among women with PCOS.24
The literature on neurobiological research in anxiety 
disorders, anxiety symptoms, depressive disorders, 
and depressive symptoms among women with PCOS 
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Figure 4 Forest plot of the studies that assessed depressive symptoms.
Abbreviation: Re model, random-effects model. Figure 5 Funnel plot of the studies that assessed depressive symptoms.
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Table 2 Leave-one-out models for the meta-analysis of anxiety symptoms
Study (year) Log odds  
ratio
SE z value P-value 95% Cl Heterogeneity
Q statistic (P-value) τ2 I2
Sahingöz et al,22 (2013) 0.874 0.410 2.128 P=0.033 0.069 to 1.679 6.686 (P=0.082) 0.357 54.2%
Moran et al,20 (2012) 1.119 0.530 2.111 P=0.034 0.080 to 2.158 8.342 (P=0.039) 0.658 62.3%
Moran et al,21 (2010) 0.887 0.435 2.039 P=0.041 0.034 to 1.739 6.970 (P=0.072) 0.403 55.8%
Asik et al,19 (2015) 0.925 0.500 1.849 P=0.064 -0.055 to 1.906 6.610 (P=0.085) 0.529 55.4%
Zueff et al,18 (2015) 1.343 0.324 4.146 P,0.001 0.708 to 1.979 1.656 (P=0.646) 0 0%
Abbreviations: SE, standard error; CI, confidence interval.
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encompasses hypothalamic–pituitary–adrenal (HPA) axis 
activity and neuroimaging studies.25
The neurophysiologic etiology of anxiety and depression 
is not fully understood but the dysregulation of the HPA axis 
has been linked to stress and, although less extensively, its 
putative association with anxiety and depression disorders 
has also been studied.26
Higher basal cortisol levels have been described in depres-
sion, panic disorder, and generalized anxiety disorders. In the 
latter condition, studies suggest that such dysregulation may 
be state dependent, as higher cortisol levels can be found in 
persons with current anxiety disorder and borderline cortisol 
levels for those with remitted symptoms.27 The maintenance 
of basal HPA tone is essential for homeostasis, which is usu-
ally disrupted in depressive and PCOS patients.25,26,28–30 There 
is evidence showing women with PCOS have several HPA 
changes such as abnormal androgen synthesis and secretion, 
enhanced peripheral metabolism of cortisol,31 compensatory 
overdrive of HPA,10 and impaired feedback inhibition is likely 
in patients with major depression.11,12 These changes might 
explain some of the underlying pathophysiological mecha-
nisms of the association between PCOS and depression.
Through imaging studies there is a body of evidence 
suggesting that lateral and medial regions of the prefrontal 
cortex (PFC) modulate amygdala and related limbic struc-
tures during effortful emotion regulation. Anxiety disorders 
may be linked to an imbalance between the PFC and the 
amygdala. Marsh et al assessed mood, metabolic function, 
and neuronal activation during an emotional task through 
functional magnetic resonance imaging, and µ-opioid recep-
tor availability using positron emission tomography within 
PCOS patients. Major findings indicated patients with PCOS 
had significantly greater activity in the PFC and ventral 
anterior cingulate cortex compared to controls.25
Clinical and research impact
Women with more serious PCOS symptoms are probably 
more likely to get treatment from their gynecologists. 
Table 3 Leave-one-out models for the meta-analysis of depressive symptoms
Excluded  
study (year)
Log odds  
ratio
SE z value P-value 95% CI Heterogeneity
Q statistic (P-value) τ2 I2
Sahingöz et al,22 (2013) 1.401 0.313 4.477 P,0.001 0.788 to 2.015 4.331 (P=0.363) 0.097 19.6%
Moran et al,20 (2012) 1.258 0.349 3.598 P,0.001 0.572 to 1.943 6.052 (P=0.195) 0.215 35.9%
Moran et al,21 (2010) 1.209 0.312 3.864 P,0.001 0.595 to 1.822 5.649 (P=0.226) 0.142 29.1%
Hollinrake et al,23 (2007) 1.065 0.276 3.851 P,0.001 0.523 to 1.607 3.340 (P=0.502) 0.002 0.4%
Asik et al,19 (2015) 1.179 0.375 3.144 P=0.001 0.444 to 1.914 5.562 (P=0.234) 0.225 32.4%
Zueff et al,18 (2015) 1.451 0.295 4.914 P,0.001 0.872 to 2.030 3.997 (P=0.406) 0.011 2.4%
Abbreviations: SE, standard error; CI, confidence interval.
It should be emphasized that consultation is an opportunity 
to assess not only the clinical aspects of PCOS but also 
the clinical symptoms of anxiety or depression that could 
be effectively treated. In addition, it is a chance to address 
concerns that are not necessarily associated with a psychiat-
ric condition or a psychiatric diagnosis (eg, marital, family, 
social issues, low level of quality of life, sexual dysfunction, 
low self-esteem) that often could be PCOS associated.
Given the seriousness of anxiety and depression condi-
tions in women with PCOS, further study of epidemiology, 
clinical features, neurobiology, disability, quality of life, 
and treatment in different settings and countries is needed 
to better understand this association.
Two other reviews analyzing the relation between depres-
sion and anxiety and PCOS were found. Both, Barry et al 
and Veltman-Verhulst et al arrived at similar conclusions 
found in this study, even though the number of articles 
investigated in those studies differed mainly due to different 
inclusion and exclusion criteria.32,33
Conclusion
Results from this systematic review indicate that specialized 
literature shows a lack of data on the association of PCOS 
and mental disorders. Only six studies were selected and even 
these used heterogeneous concepts of assessment.
Individuals with PCOS showed a greater prevalence of 
anxiety and depressive symptoms. New investigations could 
focus on establishing standard assessment procedures as well 
as undertaking a cost–benefit assessment to establish whether 
treating anxiety and depression in individuals with PCOS could 
lead to better directives on the treatment of these patients.
Limitations
This systematic review is characterized by the following limita-
tions: (1) the search for studies eligible for inclusion was per-
formed using electronic databases and only studies published in 
specialized literature, rather than in books, textbooks, or theses, 
were selected; (2) according to the criteria for inclusion in this 
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review, the selection of languages could have excluded studies 
performed in other countries or continents; (3) a reduced num-
ber of studies was included, which restricted the performance 
of a meta-analysis; (4) the instruments to assess anxiety or 
depression were different across studies; (5) the NOQAS for 
assessing the methodological quality of each study was adapted 
for the purposes of our analysis; however, inter-rater reliability 
of the scale was kept appropriate; (6) the use of obese patients16 
as a control group in one study could affect the results of this 
review. However, sensitivity analysis did not show that such a 
control group affected the study conclusions.
Suggestions for future research
New studies on the prevalence of anxiety and depression in 
individuals with PCOS are needed. Uniformity of concepts 
of PCOS, anxiety and depression in research and collabora-
tion among different centers are strategies that could promote 
knowledge about this issue. In addition, studies specifically 
aimed at the investigation of the association between PCOS 
and anxiety and/or depression in adolescents, adults, and 
other minority groups could be relevant, as well as the analy-
sis of other potential confounders (hormone therapy, medi-
cal treatment for PCOS, multiple drug interaction, etc). In 
view of the considerable potential of anxiety and depression 
disorders to impair functional ability,34 studies investigating 
whether treating these conditions could improve the outcome 
of these patients should be greatly encouraged.
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